| Literature DB >> 34827668 |
Amit Kumar Halder1,2, M Natália D S Cordeiro1.
Abstract
The inhibitors of two isoforms of mitogen-activated protein kinase-interacting kinases (i.e., MNK-1 and MNK-2) are implicated in the treatment of a number of diseases including cancer. This work reports, for the first time, a multi-target (or multi-tasking) in silico modeling approach (mt-QSAR) for probing the inhibitory potential of these isoforms against MNKs. Linear and non-linear mt-QSAR classification models were set up from a large dataset of 1892 chemicals tested under a variety of assay conditions, based on the Box-Jenkins moving average approach, along with a range of feature selection algorithms and machine learning tools, out of which the most predictive one (>90% overall accuracy) was used for mechanistic interpretation of the likely inhibition of MNK-1 and MNK-2. Considering that the latter model is suitable for virtual screening of chemical libraries-i.e., commercial, non-commercial and in-house sets, it was made publicly accessible as a ready-to-use FLASK-based application. Additionally, this work employed a focused kinase library for virtual screening using an mt-QSAR model. The virtual hits identified in this process were further filtered by using a similarity search, in silico prediction of drug-likeness, and ADME profiles as well as synthetic accessibility tools. Finally, molecular dynamic simulations were carried out to identify and select the most promising virtual hits. The information gathered from this work can supply important guidelines for the discovery of novel MNK-1/2 inhibitors as potential therapeutic agents.Entities:
Keywords: MNK-1 and MNK-2 inhibitors; mt-QSAR modeling; virtual screening
Mesh:
Substances:
Year: 2021 PMID: 34827668 PMCID: PMC8615736 DOI: 10.3390/biom11111670
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Statistical results of the mt-QSAR models generated with different model building strategies.
| Parameters | Linear Model | Non-Linear Model | Non-Linear Model | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Sub-Train | Test | Validation | Sub-Train | Test | Validation | Sub-Train | Test | Validation | |
| TP | 308 | 88 | 147 | 314 | 81 | 148 | 318 | 87 | 150 |
| TN | 674 | 154 | 362 | 653 | 152 | 361 | 660 | 158 | 365 |
| FP | 20 | 11 | 20 | 41 | 13 | 21 | 34 | 7 | 17 |
| FN | 57 | 12 | 39 | 51 | 19 | 38 | 47 | 13 | 36 |
| Sensitivity | 97.12 | 93.33 | 94.76 | 86.03 | 92.12 | 94.51 | 87.12 | 95.76 | 95.55 |
| Specificity | 84.38 | 88.00 | 79.03 | 94.09 | 81.00 | 79.57 | 95.10 | 87.00 | 80.64 |
| Accuracy | 92.73 | 91.32 | 89.61 | 91.31 | 87.92 | 89.61 | 92.35 | 92.45 | 90.67 |
| F1-score | 88.89 | 88.44 | 83.29 | 87.22 | 83.50 | 83.38 | 88.70 | 89.69 | 84.98 |
| MCC | 0.838 | 0.815 | 0.76 | na | 0.741 | 0.760 | na | 0.838 | 0.785 |
| AUROC | 0.907 | 0.907 | 0.869 | na | 0.866 | 0.870 | na | 0.914 | 0.881 |
Figure 1Flowchart showing the modification of the original FS-LDA model through PS3M refinement.
Comparison between the original FS-LDA model and the final LDA model produced by PS3M refinement.
| Model | Equation | Sub-Training | Test | Validation |
|---|---|---|---|---|
| Original | TP = 308 | TP = 88 | TP = 147 | |
| Final | TP = 310 | TP = 89 | TP = 148 |
Figure 2ROC plot of the final mt-QSAR model (left) and the absolute standardized coefficients of its descriptors (right).
Results of the condition-wise prediction for the best mt-QSAR model.
| Condition |
|
|
| Test Set | External Validation Set | ||
|---|---|---|---|---|---|---|---|
| #Instances | %Accuracy | #Instances | %Accuracy | ||||
| 1 | IC50 | B | MNK-2 | 189 | 88.36 | 107 | 92.52 |
| 2 | IC50 | B | MNK-1 | 104 | 88.46 | 40 | 92.50 |
| 3 |
| B | MNK-2 | 20 | 95.00 | 11 | 90.91 |
| 4 |
| B | MNK-1 | 31 | 96.77 | 9 | 100.00 |
| 5 |
| B | MNK-2 | 19 | 84.21 | 1 | 0.00 |
| 6 |
| B | MNK-1 | 15 | 93.33 | 5 | 100.00 |
| 7 |
| F | MNK-2 | 190 | 93.16 | 92 | 94.57 |
Results of the similarity search analysis .
| Query Compounds | Number of Matches | Average MNK-1/2 Activity | Average Similarity |
|---|---|---|---|
| Asn1051 | 45 | 1085.78 | 0.33 |
| Asn0225 | 30 | 1218.10 | 0.32 |
| Asn1125 | 14 | 646.57 | 0.32 |
| Asn2420 | 14 | 36.36 | 0.32 |
| Asn0240 | 12 | 608.00 | 0.32 |
| Asn2447 | 6 | 22.50 | 0.32 |
| Asn0252 | 4 | 2100.00 | 0.33 |
| Asn2416 | 3 | 35.00 | 0.32 |
| Asn2471 | 3 | 45.00 | 0.31 |
| Asn2459 | 2 | 36.50 | 0.31 |
| Asn2466 | 2 | 49.00 | 0.32 |
| Asn4780 | 2 | 1032.00 | 0.33 |
| Asn2422 | 1 | 46.00 | 0.31 |
| Asn2458 | 1 | 46.00 | 0.32 |
All matches in the target dataset show a Tanimoto similarity value greater than 0.3 with the query compound. In this calculation, if the inhibitory potential of a compound is expressed as < 100 nM, it was considered equal to 100 nM.
Figure 3Molecular structures of the six virtual hits chosen after the similarity search analysis.
Figure 4Six target dataset matches of Asn1051, with reported MNK-1/2 activity in the Binding Database, found by the similarity search analysis.
ADME, drug-likeness and synthetic accessibility of the virtual hit compounds as predicted by the SwissADME webserver.
| Compound | ESOL | GI | BBB | Lipinski #Violations | Veber #Violations | Synthetic Accessibility | |
|---|---|---|---|---|---|---|---|
| Asn0225 | Moderate | High | No | No | 0 | 0 | 3.06 |
| Asn0240 | Moderate | High | No | No | 0 | 0 | 3.28 |
| Asn1051 | Moderate | High | No | No | 0 | 0 | 2.77 |
| Asn1125 | Moderate | High | No | No | 0 | 0 | 2.67 |
| Asn2420 | Moderate | High | No | Yes | 0 | 0 | 4.18 |
| Asn2447 | Moderate | High | No | Yes | 0 | 0 | 4.44 |
Estimated aqueous solubility. GI: Gastrointestinal. BBB: Blood–Brain Barrier. p-gp: p-glycoprotein.
Figure 5(A) RMSD plot of MNK-2 protein complexes and (B) their associated ligands. (C) RMSD plot of MNK-1 protein complexes and (D) their associated ligands.
Calculated binding free energies (ΔGbind in kcal/mol) for the MNK-1 and MNK-2 bound ligands.
| Query Compounds | MNK-1 | MNK-2 |
|---|---|---|
| Asn1051 | −40.20 | −37.21 |
| Asn0225 | −52.97 | −35.21 |
| Asn1125 | −32.32 | −37.45 |
| Asn2420 | −38.38 | −48.94 |
| Asn0240 | −32.33 | −42.28 |
| Asn2447 | −31.88 | −29.71 |
| eFT508 | −36.41 | −44.82 |